UBS analyst Eliana Merle reiterated a Buy rating and $82.00 price target on BridgeBio Pharma (NASDAQ: BBIO).The analyst commented, "Biotechnology ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE